The AI Biopharma Brief

The global HTA and pricing landscape moves fast. The AI Biopharma Brief keeps you ahead of it. Designed for biopharma executives and market access teams, each episode distills the most critical regulatory intelligence, pricing shifts, and HTA developments into a focused, actionable briefing — no filler, no fluff.

AI Supercomputers, Wegovy's Price War & Regulatory Chaos: Pharma's Existential Crossroads 03/12/2026

AI Supercomputers, Wegovy's Price War & Regulatory Chaos: Pharma's Existential Crossroads The pharmaceutical industry is facing a perfect storm — and today's deep dive pulls it all apart. We open with the Silicon Valley-ification of big pharma, examining how Eli Lilly's new NVIDIA supercomputer and Generate Biomedicines' $400 million IPO signal a fundamental shift in drug discovery. This isn't innovation for its own sake — it's survival. Evaluate's intelligence reports are flagging a looming $300 billion patent cliff that threatens to wipe out the revenue base of the world's largest drug companies, and AI-powered supercomputing is their most credible escape route. From there, we dive into the trillion-dollar obesity war. Novo Nordisk's stunning decision to slash Wegovy's list price by 50% by 2027 looks like a shareholder nightmare on the surface — but the strategy reveals a calculated bet on a future where GLP-1 drugs become government-subsidized public health infrastructure, modeled on how global economies now frame the cost of smoking. We connect this to Norway's striking data on the 120 billion kroner annual economic burden of smoking to show exactly why governments are paying attention. Finally, we navigate the regulatory chaos defining the moment — from the FDA's brutal rare disease crackdown trapping Uniqure in an ethical bind over Huntington's disease, to Moderna receiving a refuse-to-file letter for its mRNA flu vaccine, to Europe's bold structural response: rewriting the regulatory rulebook entirely for platform technologies and building joint Nordic HTA pathways to buy smarter as a bloc. In this episode: Why Eli Lilly building an NVIDIA supercomputer is an act of financial survival, not innovation theatre The $300 billion patent cliff and why traditional drug discovery is too slow to save pharma How AI is untangling the "Wild West" of neonatal medicine to save premature babies Novo Nordisk's Wegovy price strategy and the public health economics behind it Medicare's Inflation Reduction Act negotiations and the end of arbitrary price hikes The FDA's refuse-to-file letter to Moderna — and what it means for mRNA as a platform How Europe is rewriting drug regulation from scratch to match modern science The Nordic joint HTA — why buying drugs like a Costco bulk purchase is genius policy /episode/index/show/75d5044c-353f-44f7-94cd-c04ab3059c9c/id/40414755

The Healthcare Tug of War: Medicare Fraud Crackdowns, Global Drug Pricing Wars & the FDA's AI Revolution 03/12/2026

The Healthcare Tug of War: Medicare Fraud Crackdowns, Global Drug Pricing Wars & the FDA's AI Revolution The healthcare system is at a breaking point — and today's deep dive pulls back the curtain on the forces reshaping it. We unpack the seismic Medicare Advantage upcoding crackdown, where the federal government is deploying real-time data algorithms to freeze enrollment for giants like Elevance and expose systematic fraud alleged against UnitedHealth. Then we navigate the explosive global drug pricing tug of war — from the Inflation Reduction Act's historic Medicare negotiations and Novo Nordisk's dramatic 50% Wegovy price slash, to the geopolitical firestorm of Most Favored Nation pricing and a shocking impasse in FDA user fee negotiations over domestic manufacturing mandates. Crossing the Atlantic, we examine Europe's regulatory overhaul: the push for Joint Health Technology Assessments, a critical capacity crisis in scientific consultations, and a bold new framework for approving platform technologies like mRNA delivery systems. Finally, we return to the FDA's fascinating internal contradictions — a strict rare disease crackdown demanding statistical purity, set against a revolutionary embrace of simple patient-reported outcomes and AI-powered real-world evidence to save the most vulnerable patients in the NICU. In this episode: Why a Medicare Advantage enrollment freeze is more powerful than any fine How HCC upcoding turned diagnostic codes into billion-dollar profit machines The gross-to-net pricing bubble and what Wegovy's list price cut really means Joint HTA: Europe's bold bet to fix its 27-country reimbursement nightmare The FDA's rare disease crackdown and the "let perfect be the enemy of the good" debate How AI and real-world evidence could replace clinical trials in the NICU Why the UK sees the EU AI Act as a post-Brexit pharma opportunity Whether you work in pharma, health policy, investing, or just want to understand the machinery behind your healthcare costs — this episode is essential listening. /episode/index/show/75d5044c-353f-44f7-94cd-c04ab3059c9c/id/40414430

The AI Biopharma Brief

TOPICS